https://youtu.be/HiLb1rMmyMUGday all, I’ve been watching the...

https://youtu.be/HiLb1rMmyMU

Gday all, I’ve been watching the latest Edison Open House presentation with Bob which was recorded late 2021 and released early 2022.

It’s been posted previously but just thought I’d share some points I found Interesting:

The company conducted a study in the US in terms of the cost savings to hospitals by replacing Her2 biopsy surgery with a magsense test. As Bob stated in the presentation the first thing Drs and patients want to know once breast cancer is diagnosed is “has it spread to the lymph nodes”.
The study concluded cost savings of between $500-$1000 per patient.
Considering globally there are 2.3 million breast cancers diagnosed annually (270k in US alone) there is a real cost benefit to any big hospital.
But there is also a big benefit to the patient by a avoiding surgical intervention and the after effects.

At the 11:30 mark in the presentation Bob discusses the timing of partnering with existing companies in the imaging space.

Bob mentions Siemens and GE and indicates these conversations will take place once the phase one trial is completed.

At the 14:15 mark Bob discusses shareholder value and outlines that Phase 1 study progress, progressing the R and D pipeline and developing the nano particle business as priorities and states that the company hopes to update the market in relation to the Phase 1 study in 1H 2022.

So along with the updated ANZCTR site incoming shortly, we should be well updated moving forward.

Anyways have a good weekend all

Cheers

Creep